- Fujirebio Inc. has implemented Kinaxis’ AI-powered Maestro™ platform to optimise its supply chain.
- The adoption aims to support Fujirebio’s CDMO expansion and enhance strategic decision-making.
Kinaxis has announced that Fujirebio Inc., a Japanese multinational biotechnology company, is integrating the Kinaxis Maestro™ platform to improve its supply chain operations. The move is aimed at enhancing efficiency and supporting Fujirebio’s expansion in contract development and manufacturing (CDMO).
Fujirebio, a subsidiary of Fujirebio Holdings Inc., specialises in clinical diagnostic reagents and testing equipment. The company is strengthening its CDMO services by leveraging high-quality raw materials in immunology and advanced reagent development technologies. To achieve this, it required a supply chain solution capable of synchronising complex operations from raw material production to final product shipment.
“The adoption of Kinaxis is central to building a more flexible and efficient supply chain model,” said Kazuya Saito, division head of SCM division, corporate SCM division at Fujirebio Inc. “This will enable faster strategic decision-making and accelerate our efforts toward transforming our business structure.”
By deploying Kinaxis’ Maestro platform, Fujirebio aims to improve demand, production, and procurement planning through AI-driven simulations. The implementation also supports the establishment of a Sales and Operations Planning (S&OP) process, integrating financial data into supply chain decision-making.
Phillip Teschemacher, president of APAC at Kinaxis, highlighted the importance of advanced planning in healthcare supply chains. “We are pleased to support Fujirebio as they advance strategic decision-making through the use of simulations,” he said.
